StonvexLoading…
StonvexStonvexStonvexCore line items from GMED's most recent SEC filings (10-K / 10-Q via EDGAR XBRL). Last 4 reporting periods.
Quarterly filings sourced directly from SEC EDGAR. Real-time earnings actuals are in the Earnings panel above.
| Metric | Q1 2026 2026-03-31 | Annual 2025 2025-12-31 | Q3 2025 2025-09-30 | Q2 2025 2025-06-30 |
|---|---|---|---|---|
Revenue | $759.85M | $2.94B | $2.11B | $1.34B |
Operating Income | $150.39M | $479.82M | $310.48M | $173.11M |
Net Income | $124.30M | $537.87M | $397.27M | $278.31M |
EPS (Diluted) | $0.90 | $3.92 | $2.90 | $2.01 |
Total Assets | $5.44B | $5.30B | $5.10B | $4.96B |
Total Liabilities | $707.24M | $729.51M | $696.82M | $665.41M |
Cash & Equivalents | $560.95M | $526.16M | $371.77M | $229.45M |
Free Cash Flow OCF − CapEx | $162.75M | $588.77M | $386.38M | $172.50M |
Shares Outstanding | 138.19M | 137.06M | 137.22M | 138.14M |